New Jersey Trim vs. New Jersey Trim Clinic: What People Search For

MEDICAL SOURCES & FURTHER READING

Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.

• NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity

  Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.

• Mayo Clinic — Prescription weight-loss drugs

  Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.

• Cleveland Clinic — GLP-1 Agonists

  Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.

  Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.

• Once-Weekly Semaglutide in Adults with Overweight or Obesity

  Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.

  Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.

• FDA — Wegovy (semaglutide) prescribing information

  Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.

  Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.

• Tirzepatide Once Weekly for the Treatment of Obesity

  Supports: The SURMOUNT-1 trial studied tirzepatide at different doses in adults with obesity or overweight without diabetes and reported weight reduction and gastrointestinal adverse events.

  Evidence limits: SURMOUNT-1 was placebo-controlled, not a head-to-head comparison with semaglutide. Results do not establish guaranteed outcomes or equivalence of compounded medicines.

• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

  Supports: SURMOUNT-5 directly compared maximum tolerated doses of tirzepatide and semaglutide in adults with obesity without diabetes and reported greater average weight reduction with tirzepatide at 72 weeks.

  Evidence limits: This was an open-label trial in a defined population. The finding does not determine which treatment is appropriate for an individual, establish clinic outcomes, or validate compounded formulations.

• FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

  Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.

  Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.

• A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD

  Supports: This exploratory pilot measured NAD+ and related metabolites during and after an intravenous infusion.

  Evidence limits: It did not establish anti-aging, longevity, improved energy, cognition or clinical benefit, and did not study the clinic's injection regimen. A biological role for NAD+ does not prove a treatment benefit.